Skip to main content
. 2022 Jan 25;14(3):599. doi: 10.3390/cancers14030599

Figure 1.

Figure 1

Median progression-free survivals in prospective studies of PARP inhibitors in patients with HER2 negative and HRD-associated metastatic breast cancers.Bar plot showing progression free survival (PFS) in months in different subgroups. In grey, PFS in the endocrine-receptor positive HER2 negative (ER+/HER2-) breast cancer patient subgroup from cohort 2 of the TBCRC048 study corresponding to patients with somatic pathogenic variant of BRCA1/2 genes or in other DNA repair genes. In pink, PFS in the ER+/HER2- breast cancer patient subgroup from cohort 1 of the TBCRC048 study corresponding to patients carrying a germline mutation in a DNA repair gene other than BRCA. In orange, whole cohort 2 of the TBCRC048 study. In yellow, whole cohort 1 of the TBCRC048 study. In red, PFS in the ER+/HER2- breast cancer patient subgroup with PARP inhibitor treatment. In green, PFS in the whole cohort with PARP inhibitor treatment. In blue, PFS in the whole cohort with chemotherapy alone. ** LUCY trial: Single arm study assessing Olaparib in monotherapy in real life, no placebo group.